Shanghai, China - MicroPort^® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort^® CardioFlow, stock code: 02160.HK) recently announced that following Alwide^® Plus Balloon Catheter, the second generation of balloon catheter, Its self-developed new generation Transcatheter Aortic Valve Implantation (" TAVI ") product VitaFlow Liberty^® Transcatheter Aortic Valve and Retrivable Delivery System (" VitaFlow Liberty^® ") has received marketing approval from the Russian State Food and Drug Regulatory Agency (RZN).

VitaFlow Liberty^® is the world’s only electric retrievable transcatheter aortic valve system, offering outstanding stability during procedure and hemodynamics post-procedure that will improve the quality of life for patients with aortic valve disease. It inherits the advantages of the VitaFlow^® in terms of valve design, featuring a hybrid density self-expanding stent, bovine pericardial leaflets, and a high double-layer PET skirt design. This design offers robust radial force, improved coaxiality during deployment, and effectively reduces the incidence of perivalvular leakage post-procedure. Moreover, its breakthrough upgraded delivery system incorporates a unique and innovative double-reinforced spiral structure that ensures rapid, stable, and precise release and retrieval. This system also provides flexibility, allowing for 360-degree bending of the valve segment.

Previously, MicroPort^® CardioFlow’s two generations of TAVI products, VitaFlow^® and VitaFlow Liberty^®, have fully covered more than 500 core hospitals in China and more than 80 core hospitals in overseas countries since their listing. The approval of VitaFlow Liberty^® in Russia marked another important milestone for MicroPort^® CardioFlow in the internationalization development , following Argentina, Colombia and Thailand. In the future, MicroPort^® CardioFlow will continue to develop innovative technologies and launch more internationally competitive products to provide high-quality, universal total solutions for structural heart disease to more patients around the world.